These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intensification of chelating-therapy in patients with thalassemia major. Laws HJ; Göbel U; Christaras A; Janssen G Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702 [TBL] [Abstract][Full Text] [Related]
4. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Wali YA; Taqi A; Deghaidi A Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089 [TBL] [Abstract][Full Text] [Related]
5. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study]. Cario H; Stahnke K; Kohne E Klin Padiatr; 1999; 211(6):431-7. PubMed ID: 10592921 [TBL] [Abstract][Full Text] [Related]
6. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. Viprakasit V; Tanphaichitr VS; Mahasandana C; Assteerawatt A; Suwantol L; Veerakul G; Kankirawatana S; Pung-Amritt P; Suvatte V J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973 [TBL] [Abstract][Full Text] [Related]
7. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major]. Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563 [TBL] [Abstract][Full Text] [Related]
8. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
9. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia. Aessopos A; Kati M; Tsironi M; Polonifi E; Farmakis D Haematologica; 2006 May; 91(5 Suppl):ECR11. PubMed ID: 16709519 [TBL] [Abstract][Full Text] [Related]
10. Methods for noninvasive measurement of tissue iron in Cooley's anemia. Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684 [TBL] [Abstract][Full Text] [Related]
11. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202 [TBL] [Abstract][Full Text] [Related]
12. [Therapeuetic management of patients with thalassemia major]. Thuret I Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036 [TBL] [Abstract][Full Text] [Related]
13. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. Bronspiegel-Weintrob N; Olivieri NF; Tyler B; Andrews DF; Freedman MH; Holland FJ N Engl J Med; 1990 Sep; 323(11):713-9. PubMed ID: 2388669 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. Brittenham GM; Griffith PM; Nienhuis AW; McLaren CE; Young NS; Tucker EE; Allen CJ; Farrell DE; Harris JW N Engl J Med; 1994 Sep; 331(9):567-73. PubMed ID: 8047080 [TBL] [Abstract][Full Text] [Related]
15. Desferrioxamine induced urinary iron excretion in thalassemia. Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258 [TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of infused iron chelation therapy in the United States. Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607 [TBL] [Abstract][Full Text] [Related]
17. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy. Christoforidis A; Perifanis V; Tsatra I; Vlachaki E; Athanassiou-Metaxa M Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760 [TBL] [Abstract][Full Text] [Related]
18. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155 [TBL] [Abstract][Full Text] [Related]
19. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. Wolfe L; Olivieri N; Sallan D; Colan S; Rose V; Propper R; Freedman MH; Nathan DG N Engl J Med; 1985 Jun; 312(25):1600-3. PubMed ID: 4000198 [TBL] [Abstract][Full Text] [Related]
20. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major. Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]